BioSpace News Archive

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported financial results for the third quarter ended September 30, 2021.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1/2 triple combination dose escalation study evaluating the combination of COM701.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of new translational preliminary data detailing the differentiated profile of PVRIG compared to TIGIT and PD-1 as a novel checkpoint in the DNAM axis.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new study data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

CASI Pharmaceuticals, Inc., is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported financial results for the third quarter of 2021.

A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of a first-in-class Tmod™ T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells.

Xencor, Inc. today reported data from its Phase 1 study evaluating vudalimab (XmAb®717), a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (DUET-2).

Nkarta, Inc. today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs.

BioLineRx Ltd. announced today it will release its unaudited financial results for the quarter ended September 30, 2021 on Thursday, November 18, 2021, before the US markets open.

Appili Therapeutics Inc. today announced that the Phase 3 PRESECO did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing.